111 related articles for article (PubMed ID: 36263960)
1. Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.
Tyagi A; Tong Y; Rabideau DJ; Reynolds Z; De Oliveira T; Lessells R; Amanyire G; Orrell C; Asiimwe S; Chimukangara B; Giandhari J; Pillay S; Haberer JE; Siedner MJ;
Antivir Ther; 2022 Oct; 27(5):13596535221114822. PubMed ID: 36263960
[TBL] [Abstract][Full Text] [Related]
2. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after virologic failure of first-line ART in South Africa.
Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
[TBL] [Abstract][Full Text] [Related]
4. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
Boyce CL; Beck IA; Styrchak SM; Hardy SR; Wallner JJ; Milne RS; Morrison RL; Shapiro DE; João EC; Mirochnick MH; Frenkel LM
PLoS One; 2022; 17(9):e0275254. PubMed ID: 36166463
[TBL] [Abstract][Full Text] [Related]
5. Who's slipping through the cracks? A comprehensive individual, clinical and health system characterization of people with virological failure on first-line HIV treatment in Uganda and South Africa.
Reynolds Z; McCluskey SM; Moosa MYS; Gilbert RF; Pillay S; Aturinda I; Ard KL; Muyindike W; Musinguzi N; Masette G; Moodley P; Brijkumar J; Rautenberg T; George G; Johnson BA; Gandhi RT; Sunpath H; Marconi VC; Bwana MB; Siedner MJ
HIV Med; 2022 May; 23(5):474-484. PubMed ID: 34755438
[TBL] [Abstract][Full Text] [Related]
6. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.
El-Khatib Z; Ekstrom AM; Coovadia A; Abrams EJ; Petzold M; Katzenstein D; Morris L; Kuhn L
BMC Public Health; 2011 Feb; 11():88. PubMed ID: 21303548
[TBL] [Abstract][Full Text] [Related]
7. Long-term virologic responses to antiretroviral therapy among HIV-positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal analysis.
Kehoe K; Boulle A; Tsondai PR; Euvrard J; Davies MA; Cornell M
J Int AIDS Soc; 2020 May; 23(5):e25476. PubMed ID: 32406983
[TBL] [Abstract][Full Text] [Related]
8. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase.
Gardner EM; Melendez AG; Astiz M; Bray K
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(1):34-9. PubMed ID: 21972263
[TBL] [Abstract][Full Text] [Related]
9. Participants Switching to Second-Line Antiretroviral Therapy with Susceptible Virus Display Inferior Adherence and Worse Outcomes: An Observational Analysis.
Mantshonyane L; Roy J; Levy MZ; Wallis CL; Bar K; Godfrey C; Collier A; LaRosa A; Zheng L; Sun X; Gross R
AIDS Patient Care STDS; 2021 Dec; 35(12):467-473. PubMed ID: 34788110
[TBL] [Abstract][Full Text] [Related]
10. ART adherence and viral suppression are high among most non-pregnant individuals with early-stage, asymptomatic HIV infection: an observational study from Uganda and South Africa.
Haberer JE; Bwana BM; Orrell C; Asiimwe S; Amanyire G; Musinguzi N; Siedner MJ; Matthews LT; Tsai AC; Katz IT; Bell K; Kembabazi A; Mugisha S; Kibirige V; Cross A; Kelly N; Hedt-Gauthier B; Bangsberg DR
J Int AIDS Soc; 2019 Feb; 22(2):e25232. PubMed ID: 30746898
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Appraising Viral Load Thresholds and Adherence Support Recommendations in the World Health Organization Guidelines for Detection and Management of Virologic Failure.
McCluskey SM; Boum Y; Musinguzi N; Haberer JE; Martin JN; Hunt PW; Marconi VC; Bangsberg DR; Siedner MJ
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):183-187. PubMed ID: 28628529
[TBL] [Abstract][Full Text] [Related]
12. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
Castelnuovo B; Kiragga A; Mubiru F; Kambugu A; Kamya M; Reynolds SJ
J Int AIDS Soc; 2016; 19(1):20773. PubMed ID: 27319742
[TBL] [Abstract][Full Text] [Related]
13. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Shearer K; Brennan AT; Maskew M; Long L; Berhanu R; Sanne I; Fox MP
J Int AIDS Soc; 2014; 17(1):19065. PubMed ID: 25361827
[TBL] [Abstract][Full Text] [Related]
14. Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study.
Court R; Leisegang R; Stewart A; Sunpath H; Murphy R; Winternheimer P; Ally M; Maartens G
BMC Infect Dis; 2014 Dec; 14():664. PubMed ID: 25472544
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Chen J; Zhang M; Shang M; Yang W; Wang Z; Shang H
BMC Infect Dis; 2018 Nov; 18(1):571. PubMed ID: 30442114
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral Adherence, Elevated Viral Load, and Drug Resistance Mutations in Human Immunodeficiency Virus-infected Women Initiating Treatment in Pregnancy: A Nested Case-control Study.
Myer L; Redd AD; Mukonda E; Lynch BA; Phillips TK; Eisenberg A; Hsiao NY; Capoferri A; Zerbe A; Clarke W; Lesosky M; Breaud A; McIntyre J; Bruno D; Martens C; Abrams EJ; Reynolds SJ
Clin Infect Dis; 2020 Jan; 70(3):501-508. PubMed ID: 30877752
[TBL] [Abstract][Full Text] [Related]
19. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
[TBL] [Abstract][Full Text] [Related]
20. The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.
Penot P; Héma A; Bado G; Kaboré F; Soré I; Sombié D; Traoré JR; Guiard-Schmid JB; Fontanet A; Slama L; Bruno Sawadogo A; Laurent C
J Int AIDS Soc; 2014; 17(1):18646. PubMed ID: 24433983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
